BioMarin Pharmaceutical Inc.
About BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. In 1997, the company was founded to make a big difference in small patient populations, focusing on giving much-needed attention to the underserved communities of those with rare diseases. BioMarin sought to help patients whose voices could not always be heard and treat conditions that were not always in mainstream medical conversations. Throughout its history, BioMarin has worked tirelessly to make a difference by pursuing bold science. The company’s first approved therapy was inspired by a father who refused to accept there was no therapy for his son’s rare diagnosis. That relentless pursuit to change the course of his son’s future through the power of science is at the core of who BioMarin is today.
Through the company’s expertise in genetics and molecular biology, BioMarin has developed eight first or best-in-class targeted therapies that address the root cause of the conditions it seeks to treat, helping to better the lives of those struggling with rare genetic disease. The company’s purposeful and scientifically precise team of physicians and scientists has honed each treatment modality to seek transformative therapies.
Now, BioMarin seeks to make an even greater impact by applying the same science-driven, patient-forward approach that propelled the last 25 plus years of drug development to larger genetic disorders, as well as genetic subsets of more common conditions. Each drug candidate pursued is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. The company believes that applying its knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most. The more innovative solutions developed, the more lives BioMarin can impact.
841 articles about BioMarin Pharmaceutical Inc.
-
BioMarin Pharmaceutical Inc. to Present at the UBS Global Life Sciences Conference
9/13/2011
-
BioMarin Pharmaceutical Inc. to Present at the Morgan Stanley Global Healthcare Conference
9/7/2011
-
BioMarin Pharmaceutical Inc. to Present at the Baird Health Care Conference
8/30/2011
-
BioMarin Pharmaceutical Inc. to Present at the Wedbush Life Sciences Conference
8/9/2011
-
BioMarin Pharmaceutical Inc. Provides Update on GALNS Phase 1/2 Extension Study (MOR-100)
7/29/2011
-
BioMarin Pharmaceutical Inc. Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
7/15/2011
-
BioMarin Pharmaceutical Inc. to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
6/30/2011
-
BioMarin Pharmaceutical Inc. to Buy Pfizer Inc.'s Cork Plant for $48.5 Million, to Create 100 Jobs
6/23/2011
-
BioMarin Pharmaceutical Inc. to Present at the William Blair Growth Stock Conference
6/8/2011
-
BioMarin Pharmaceutical Inc. to Present at the Jefferies and Co. Global Healthcare Conference
5/31/2011
-
BioMarin Pharmaceutical Inc. to Present at the UBS Global Specialty Pharmaceuticals Conference
5/18/2011
-
BioMarin Pharmaceutical Inc. to Present at the Bank of America Merrill Lynch Healthcare Conference
5/3/2011
-
BioMarin Pharmaceutical Inc. Announces First Quarter 2011 Financial Results
4/29/2011
-
BioMarin Pharmaceutical Inc. to Present at the Deutsche Bank Healthcare Conference
4/26/2011
-
BioMarin Pharmaceutical Inc. Opts Out of Aldurazyme Control
4/6/2011
-
BioMarin Pharmaceutical Inc. to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET
3/28/2011
-
BioMarin Pharmaceutical Inc. to Present at the Cowen and Company Health Care Conference
3/1/2011
-
BioMarin Pharmaceutical Inc. to Present at the Citi Global Healthcare Conference
2/22/2011
-
BioMarin Pharmaceutical Inc. Announces Fourth Quarter and Full Year 2010 Financial Results
2/18/2011
-
BioMarin Pharmaceutical Inc. Expands as it Tests New Drugs, Plans to Create 100 New Jobs This Year
2/14/2011